ClinicalTrials.gg
RecruitingNCT07392255Opti-GAINUpdated Oct 16, 2026

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

A Phase 1/2 interventional study of CTx001 in Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by Complement Therapeutics. Recruiting at 8 sites in 2 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Complement Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Oct 16, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
57th of 107
75 · median 98
Started
2025
with 19 others
Phase 1/2
17 of 131
7 open now
Primary completion
2028-05
later than 25 of 44 live
Registered
123rd of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 57th largest by planned enrollment of the 107 interventional ones that give a count, is one of 20 that started in 2025, is one of 17 in phase 1/2, reaches primary completion later than 25 of the 44 other live ones, and was the 123rd registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD).

Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.

03

Conditions studied

  • Geographic Atrophy Secondary to Age-related Macular Degeneration
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Meet protocol-defined age eligibility

Have bilateral geographic atrophy secondary to AMD, confirmed by the Reading Center

Meet baseline lesion size requirements, as assessed by fundus autofluorescence imaging

Meet best-corrected visual acuity and low-luminance visual acuity criteria, as measured by ETDRS charts

Meet retinal sensitivity criteria, as measured by microperimetry

Have sufficient fellow-eye visual function to ensure navigational vision

Have adequate historical SD-OCT imaging available for longitudinal assessment

Meet reproductive status and requirements, where applicable

Be able and willing to provide and comply with study procedures

Exclusion criteria

Exclusion Criteria:

Macular atrophy or retinal disease not attributable to AMD

Evidence of current or prior choroidal neovascularization (wet AMD)

Prior intraocular, macular, or retinal surgery or laser treatment that may confound assessments

Prior AMD-directed or intravitreal therapy in the study eye, except permitted supplements

Prior exposure to complement inhibitor therapies

Ocular conditions, infections, inflammation, or media opacities that interfere with safety or retinal imaging

Uncontrolled glaucoma, diabetic retinopathy, or refractive error

Aphakia or compromised posterior capsule, except as permitted by protocol

Systemic medical or psychiatric conditions that may increase risk or limit compliance

Recent participation in another interventional clinical study or exposure to therapies

Any condition that, in the investigator's judgment, poses unacceptable risk or precludes safe participation

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Low Dose

    Genetic: CTx001

  • Experimental
    Cohort 2

    Medium Dose

    Genetic: CTx001

  • Experimental
    Cohort 3

    High Dose

    Genetic: CTx001

  • Experimental
    Cohort 4

    Expansion of a dose selected from Cohort 1-3

    Genetic: CTx001

  • Experimental
    Cohort 5

    Expansion of a second dose selected from Cohort 1-3

    Genetic: CTx001

Interventions

  • GeneticCTx001

    Subretinal administration of CTx001

06

What researchers measure

Primary outcomes

  1. To monitor the safety and tolerability of a single administration of CTx001 at 3 dose levels

    Incidence and severity of ocular and non-ocular adverse events (AE)s and serious AEs (SAEs) up to Week 52 (Year 1)

    Time frame: From dosage to Week 52

Secondary outcomes

  1. To evaluate the preliminary efficacy of treatment with CTx001 through changes in the structural and functional parameters of geographic atrophy (GA)

    Change from baseline in the rate of total ellipsoid zone (EZ) attenuation as measured by spectral domain-optical coherence tomography (SD-OCT) at Week 52 (Year 1)

    Time frame: From dosage to Year 1

  2. To evaluate the preliminary efficacy of treatment with CTx001 through changes in the structural and functional parameters of geographic atrophy (GA)

    Rate of change from baseline in sensitivity as measured by microperimetry at Week 52 (Year 1)

    Time frame: From dosage to Year 1

  3. To evaluate the preliminary efficacy of treatment with CTx001 through changes in the structural and functional parameters of geographic atrophy (GA)

    Change from baseline in low luminance visual acuity (LLVA) as measured by Early Treatment Diabetic Retinopathy Study (EDTRS) chart and neutral density filter at Week 52 (Year 1)

    Time frame: From dosage to Year 1

  4. To evaluate the preliminary efficacy of treatment with CTx001 through changes in the structural and functional parameters of geographic atrophy (GA)

    Change from baseline in the rate of enlargement of lesion area of geographic atrophy as measured by Fundus Auto Fluorescence (FAF) at Week 104 (Year 2)

    Time frame: From dosage to Year 2

  5. To evaluate the preliminary efficacy of treatment with CTx001 through changes in the structural and functional parameters of geographic atrophy (GA)

    Change from baseline in best corrected visual acuity (BCVA) as measured by Early Treatment Diabetic Retinopathy Study (EDTRS) chart at Week 104 (Year 2)

    Time frame: From dosage to Year 2

  6. To monitor the long-term safety and tolerability of a single administration of CTx001 at 3 dose levels

    * Incidence and severity of ocular and non-ocular AEs and SAEs up to Week 260 (Year 5) * Incidence and extent of retinal pigmentary changes up to Week 260 (Year 5)

    Time frame: From dosage up to Week 260 (Year 5)

  7. To assess immunogenicity to adeno-associated virus Serotype 2 (AAV2)-vector and mini-CR1 transgene product

    Measurement of systemic antibody levels to AAV2-vector and mini-CR1 transgene up to Week 260 (Year 5)

    Time frame: From dosage up to Week 260 (Year 5)

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for May 2028, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Feb 6, 2026
StartActual
Dec 30, 2025
Primary completionEst.
May 31, 2028
CompletionEst.
Jun 30, 2032
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United Kingdom)
  • Gloucestershire Royal Hospital · Gloucester, United Kingdom
  • Sunderland Specialist Eye Hospital · Sunderland, United Kingdom
  • Moorfields Eye Hospital · London, United Kingdom
across 2 updates, Oct 8, 2026 – Oct 16, 2026
Show all 2 updates
  1. Oct 16, 2026
    1 site added
    Show site
    • Moorfields Eye Hospital · London, United Kingdom
  2. Oct 8, 2026
    2 sites added
    Show 2 added (2 United Kingdom)
    • Gloucestershire Royal Hospital · Gloucester, United Kingdom
    • Sunderland Specialist Eye Hospital · Sunderland, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07392255
Lead sponsor
Complement Therapeutics
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Dec 30, 2025
Primary completion
May 31, 2028 (estimated)
Completion
Jun 30, 2032 (estimated)
Last update
Oct 16, 2026

Study contacts

Muhammad Ali Memon
Contact
clinicaltrials@complementtx.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion